Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13208363 | 0.84 | GABRA1 (0.33) | GABRA1GABRB2POLB | |
| SCHEMBL13208373 | 0.84 | GABRA1 (0.33) | GABRA1GABRB2POLB | |
| SCHEMBL13208354 | 0.84 | GABRA1 (0.33) | GABRA1GABRB2POLBGAA | |
| SCHEMBL1754079 | 0.77 | HDAC8 (0.42) | GAAMAPTRXRARXRBALDH1A1 | |
| SCHEMBL93161 | 0.76 | GABRA1 (0.69) | GABRA1GABRB2POLBKDM4EGAA | |
| SCHEMBL13208447 | 0.75 | — | — | |
| SCHEMBL4402383 | 0.74 | TSHR (0.48) | MAPTALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL10394690 | 0.73 | GABRA1 (0.65) | GABRA1GABRB2POLBKDM4EGAA | |
| SCHEMBL10415675 | 0.73 | GABRA1 (0.65) | GABRA1GABRB2POLBKDM4EGAA | |
| Hydrochloric Acid SCHEMBL28547461 | 0.72 | GABRA1 (0.44) | GABRA1GABRB2POLBKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696679-A1 | CHIRAL PYRIDINIUM SALT CARBONYL CATALYST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Normal University (CN) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025002445-A1 | CHIRAL PYRIDINIUM SALT CARBONYL CATALYST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海师范大学 | 2025-01-02 | — | — | WO | disclosed |
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | JOHN VARGHESE | 2010-06-10 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7544717-B2 | 2-amino- and 2-thio- substituted 1,3-diaminopropanes | ELAN PHARMACEUTICALS, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145056-A1 | ACETYL 2-HYDROXY-1,3-DIAMINOALKANES | BACE1, BACE2, APP | GABRA1 3518/4885GABRB2 3239/4885POLB 1363/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | GABRA1 3518/4885GABRB2 3239/4885POLB 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.